

## DiaMedica Therapeutics to Report First Quarter 2021 Financials and Provide a Business Update May 6, 2021

MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that its first quarter 2021 financial results will be released after the markets close on Wednesday, May 5<sup>th</sup>. DiaMedica will host a live conference call on Thursday, May 6<sup>th</sup> at 7:00 AM Central Time to discuss its business update and financial results.

## Conference Call details:

Date: Thursday, May 6, 2021
Time: 7:00 AM CT / 8:00 AM ET

Web access: <a href="https://event.on24.com/wcc/r/3081283/E7DD7636B9914C65BD79123196FDA60B">https://event.on24.com/wcc/r/3081283/E7DD7636B9914C65BD79123196FDA60B</a>

Dial In: (866) 393-4306 (domestic)

(734) 385-2616 (international)

Conference ID: 2966016

Interested parties may access the conference call by dialing in or listening to the simultaneous webcast. Listeners should log on to the website or dial in 15 minutes prior to the call. The webcast will remain available for play back on our website, under investor relations - events and presentations, following the earnings call and for 12 months thereafter. A telephonic replay of the conference call will be available until May 13, 2021, by dialing (855) 859-2056 (US Toll Free), (404) 537-3406 (International), and entering the replay passcode: 2966016.

## About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) is a clinical stage biopharmaceutical company focused on developing novel treatments to improve the lives of patients with neurological and chronic kidney diseases. To learn more about DiaMedica, please visit www.diamedica.com.

View source version on businesswire.com: <a href="https://www.businesswire.com/news/home/20210428005679/en/">https://www.businesswire.com/news/home/20210428005679/en/</a>

Scott Kellen Chief Financial Officer Phone: (763) 496-5118 skellen@diamedica.com

For Investor Inquiries:

Tim McCarthy
Managing Director, LifeSci Advisors, LLC
tim@lifesciadvisors.com

Source: DiaMedica Therapeutics Inc.